LEXICON PHARMACEUTICAL

New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

30 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

17 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

11 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients

09 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

09 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

28 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

26 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference

07 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

21 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

08 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

03 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

28 Jul 2023 15:01:00 By Nasdaq GlobeNewswire

Lexicon Elects Diane E. Sullivan to Board of Directors

28 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

23 Jun 2023 19:45:00 By Nasdaq GlobeNewswire

Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions

20 Jun 2023 07:00:02 By Nasdaq GlobeNewswire

UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

15 Jun 2023 16:00:30 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference

06 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

05 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire